Clinical Significance of MiR-21-5p in Predicting Occurrence and Progression of Uremic Vascular Calcification in Patients with End-Stage Renal Disease
Overview
Affiliations
Purpose: Vascular calcification (VC) is a common complication of end-stage renal disease (ESRD). This study aimed to examine changes in the expression of miR-21-5p in ESRD patients with VC and to explore its clinical value in predicting the occurrence and progression of uremic VC.
Materials And Methods: 120 ESRD patients were divided into patients without VC group (n=38) and patients with VC group (n=82). All patients were followed up for 2 years to evaluate VC progression. qRT-PCR was used to detect serum miR-21-5p levels. Receiver operating characteristic curves were constructed to assess diagnostic value. Kaplan-Meier and log-rank methods were utilized to calculate associations between VC progression and risk factors.
Results: Serum miR-21-5p levels were significantly higher in ESRD patients with VC than in those without VC and increased progressively with increasing disease severity. Serum miR-21-5p levels were able to distinguish patients with VC from those without VC, with an area under the curve value of 0.883, a sensitivity of 81.7%, and a specificity of 84.2%. After 2 years of follow-up, miR-21-5p expression had increased in patients with worse VC severity, compared with those with stable VC severity. Patients with high miR-21-5p levels were more likely to develop more severe VC, indicating an association between miR-21-5p and VC progression (log-rank =0.002). Multivariable Cox regression analysis suggested that serum miR-21-5p is an independent predictive factor of VC progression in ESRD patients (hazard ratio=2.064, 95% confidence interval=1.225-3.478, =0.006).
Conclusion: miR-21-5p is overexpressed in the serum of ESRD patients with VC. Our results suggest that overexpression of miR-21-5p is closely associated with VC progression.
Management of high-flow arteriovenous access.
Park H, Shin S Kidney Res Clin Pract. 2025; 44(1):58-68.
PMID: 39923807 PMC: 11838845. DOI: 10.23876/j.krcp.23.196.
Barrera-Vazquez O, Escobar-Ramirez J, Magos-Guerrero G J Xenobiot. 2024; 14(4):1519-1540.
PMID: 39449424 PMC: 11503387. DOI: 10.3390/jox14040083.
Lu W, Guo Y, Liu H, Zhang T, Zhang M, Li X Biomater Res. 2024; 28:0013.
PMID: 38617751 PMC: 11014086. DOI: 10.34133/bmr.0013.
Jin J, Cheng M, Wu X, Zhang H, Zhang D, Liang X Clin Kidney J. 2024; 17(3):sfae038.
PMID: 38524234 PMC: 10960567. DOI: 10.1093/ckj/sfae038.
MicroRNA-218-5p regulates inflammation response via targeting TLR4 in atherosclerosis.
Chen J, Tang Z, Chen Z, Wei Y, Liang H, Zhang X BMC Cardiovasc Disord. 2023; 23(1):122.
PMID: 36890438 PMC: 9996974. DOI: 10.1186/s12872-023-03124-y.